glp-1
Excellus BlueCross BlueShield says GLP-1 drugs for diabetes will remain on formulary, countering reports of a blanket halt. Effective January 1, 2026, three GLP-1s for weight loss—Wegovy, Zepbound, and Saxenda—will be removed from covered lists for certain plans, though members can seek exceptions if prescribers verify criteria. The insurer cites Pharmacy & Therapeutics Committee review […]
Eli Lilly announced promising results for orforglipron, a once-daily weight-loss pill that helped patients with diabetes lose up to 8% of their body weight in trials. The GLP-1 drug, which avoids injections like Wegovy and Zepbound, could reshape the obesity treatment market. Side effects are similar to injectable options. With FDA approval expected in late […]
-
Pages
WDKX Holiday Stream